证券代码：002203 证券简称：海亮股份 浙江海亮股份有限公司投资者关系活动记录表 编号：2025005 投 资 者 关 系 活 动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参 与 单 位 名 称 及人员姓名 具体参会名单详见附件 时间 2025 年 5 月 14 日（周三） 地点 浙江省杭州市滨江区海亮科研大厦会议室 上 市 公 司 接 待 人员姓名 董事会秘书 童莹莹 投资者关系活 动主要内容介 绍 董事会秘书童莹莹女士向投资者介绍了海亮股份的发展历 程、使命愿景、产品服务、全球布局、对外投资、未来展望等。 公司就投资者在本次调研活动中提出的问题进行了回复： 问题一、请问公司在全球拥有 23 个生产基地，未来在海外 市场拓展方面有哪些具体计划？管理层对海外基地未来的经营 预期如何？ 您好！公司在全球范围内布局 23 个生产基地，国内基地覆 盖浙江、上海、安徽、广东、四川、重庆、甘肃、山东等省市， 而海外基地则遍及美国、德国、法国、意大利、西班牙、越南、 泰国、印度尼西亚、摩洛哥等国家。 公司管理层以前瞻性战略眼 ...

5月22日，2025年全球贸易投资促进峰会在北京钓鱼台国宾馆举办。丹麦企业家、中国丹麦商会全国创 始会长李曦萌(外文名:西蒙·利希滕贝格)在回答21世纪经济报道记者提问时表示，中国已经在绿色转 型、自动化方面走在世界前列，在很多新兴领域也取得了长足发展，中丹商业合作有广阔的前景。 他还说，中国制造业拥有庞大的人才队伍，尤其是在智能制造等高端领域，人才储备丰富，技术能力强 。在全球范围内，中国制造业在效率、质量和人才方面具有明显优势。 他进一步指出，丹麦在绿色技术转型方面做出了很多贡献，在水处理、低能耗、新能源、废物回收、供 暖和制冷、建筑设计等领域拥有领先的技术，中国和丹麦在这些方面有很大的合作潜力。 今年是中国和丹麦建交75周年。李曦萌表示，希望中丹关系越来越好，共同为全球化发展贡献力量。在 他看来，各国只有合作，才能推动和平发展，让各国人民受益。 李曦萌1987年到复旦大学学习中文和中国文化，后在上海成家立业，成为扎根中国的外国企业家，经历 并见证了中国的崛起与担当。他在中国工作和生活超过30年。 0:00 他在接受记者采访时表示，自改革开放以来，中国发生了翻天覆地的变化。近年来，中国大力推动制造 业高质 ...

Core Insights - The company achieved significant historical breakthroughs in market share, international business revenue, and high-end equipment and service revenue in 2024, driven by globalization and a "high-profile" strategy [1] - The company reported a revenue of 10.3 billion yuan and a net profit of 1.262 billion yuan for 2024, with a revenue of 2.478 billion yuan and a net profit of 370 million yuan for Q1 2025, showing growth of 5.42% and 1.87% respectively [2] - The company plans to enhance its overseas business capabilities and local marketing and service systems, aiming for global business expansion and long-term partnerships with clients [2] Financial Performance - In 2024, the company’s overseas business revenue reached 2.266 billion yuan, a year-on-year increase of 35.07%, accounting for 22% of total revenue [2] - The overall market size for medical device bidding in Q1 2025 grew approximately 67% year-on-year, indicating a recovery in the industry [2] R&D and Innovation - The company invested 2.261 billion yuan in R&D in 2024, representing 21.95% of its revenue, an increase of 5.14 percentage points year-on-year [3] - The company launched over 20 innovative products in 2024 and Q1 2025, focusing on both clinical and high-end research products [3] - The company is leveraging AI technology to transform the medical imaging industry, developing a comprehensive digital platform across product lines [3] Market Trends - The medical device industry is experiencing a recovery due to the implementation of equipment update policies and the initiation of medical device update projects [4][5] - The government’s long-term policy from 2024 to 2027 is expected to activate potential demand in the medical device market [5] - The international market for medical devices is expanding, with companies enhancing their local presence and collaboration with strategic partners [6] Industry Outlook - The Chinese medical device industry benefits from advantages in engineering, skilled labor, and a complete supply chain, leading to competitive global pricing [8] - The trend of medical devices moving from low-end to mid-to-high-end products is evident, with a focus on high-end equipment and in vitro diagnostics [8]

在全球化浪潮的推动下，深圳证券交易所市场(以下简称"深市")上市公司正以创新为桨、实力为帆，积 极拓展海外市场，谱写国际化发展的新篇章。2024年，深市公司实现海外收入4.18万亿元，同比增长 11.62%。 行业龙头企业海外销售持续增长。立讯精密（002475）工业股份有限公司(以下简称"立讯精密")、比亚 迪（002594）股份有限公司(以下简称"比亚迪")、美的集团（000333）股份有限公司(以下简称"美的集 团")、潍柴动力（000338）股份有限公司(以下简称"潍柴动力")、宁德时代（300750）新能源科技股份 有限公司(以下简称"宁德时代")5家公司2024年海外业务收入超千亿元，分别为2354.67亿元、2218.85亿 元、1690.34亿元、1197.74亿元、1103.36亿元。出口导向型公司业绩进一步增长，2024年相关公司营业 收入合计1.78万亿元，同比增长14.6%，净利润合计1229.96亿元，同比增长26.36%。 业内人士认为，从智能制造到数字经济，从绿色能源到消费升级，深市企业正将"中国智造"的品牌魅力 辐射世界，为全球产业链注入新动能。 出海步伐加快 实现全球产业链协 ...

Group 1: Overseas Business Development - In 2024, the company's overseas business generated revenue of 154 million CNY, accounting for 12.74% of total revenue [1] - The sales proportion to the U.S. market is currently small, but the company is actively expanding its global strategy [1] - The company has established a spare parts warehouse and maintenance station in Singapore and has achieved supply qualifications in Dubai and small-scale supply in Turkey [1] Group 2: Business Development Focus - In 2025, the company will continue to adhere to the development philosophy of "revitalizing the industry and serving the country through technology" [2] - The company aims to strengthen its competitive advantages in traditional sectors such as port machinery, metallurgy, and water conservancy [2] - The company plans to enhance its overseas marketing network and focus on emerging sectors like rail transit, wind power, and aviation [2] Group 3: Share Repurchase and Equity Incentives - The company has disclosed its share repurchase progress on May 6, 2025, and will formulate plans for the repurchased shares based on actual conditions [2] - The company will ensure compliance with relevant approval procedures and timely information disclosure regarding the handling of repurchased shares [2] Group 4: Technological Advantages - The company has established multiple research platforms, including a national-level postdoctoral research station and a provincial-level enterprise technology center [2] - Since 2023, the company has added a provincial industrial design center and a research center for industrial braking systems [2] - The company has developed over 80 series of new products and is involved in 42 provincial-level research projects, achieving international advanced technical standards [2] Group 5: Shareholder Information - As of March 31, 2025, Zhuhai Heavy Industry held 19.55 million shares, representing 4.65% of the company's total shares [3] - Shareholders holding less than 5% are not required to disclose their share reduction activities [3]

Group 1: Core Competitiveness and Market Strategy - The company has established a comprehensive autonomous layout from core components to complete machine manufacturing and system integration, enhancing its competitive advantages in technology, quality, cost, service, and brand [3][4]. - The strategy focuses on a "general + segmented" market approach, customizing developments for specific clients in niche markets, and maintaining leadership in sectors like new energy, metal processing, automotive, electronics, and welding [4]. - The company aims to drive industrial robots towards high precision, heavy load, and scenario-based applications, leveraging core automation technologies [4]. Group 2: Measures to Achieve Profitability - In 2025, the company will implement a strategy centered on "global layout - strategic focus - technological breakthroughs - operational efficiency" to improve operations and achieve profitability [5]. - Specific measures include optimizing the marketing system, enhancing product competitiveness through increased R&D investment, and expanding overseas markets [5][6][7]. - The company plans to strengthen internal management to reduce costs and improve efficiency, thereby gradually enhancing gross margin levels [7]. Group 3: Revenue Challenges and Recovery Plans - The industrial robot and intelligent manufacturing system business saw a revenue decline of 16.04% in 2024, primarily due to fluctuations in international and domestic market demands [8][9]. - The decline was significantly influenced by the performance of the wholly-owned subsidiary, Germany's KUKA, which faced reduced demand in the heavy industry sector and inflationary pressures in Europe [8][12]. - The company is focusing on market expansion, new product development, and resource integration to strengthen its core competitiveness and recover growth [8][9]. Group 4: Inventory and Cash Flow Management - Inventory increased by 28.41% year-on-year, mainly due to material reserves for large customer orders and pending project acceptances [9]. - The company is enhancing inventory management through demand forecasting and supply chain collaboration to improve turnover rates and reduce capital occupation [9][10]. - To address cash flow pressures, the company is focusing on improving profitability and accelerating accounts receivable recovery [10]. Group 5: Overseas Market Expansion - The company plans to continue expanding into Europe, America, the Middle East, and Southeast Asia, targeting opportunities with leading domestic clients in the new energy vehicle and lithium battery sectors [11][13]. - It aims to establish a global production base in Poland and build a global supply chain to adapt to international market changes [11]. - The company is also forming an international sales team to enhance its global business layout and improve its core technology level [13].

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 5.27% and a transaction volume of 13.6062 million yuan, with an average daily transaction volume of 28.9853 million yuan over the past month [2] - The ETF has experienced a notable increase in scale, growing by 1.7471 million yuan over the past week, ranking first among comparable funds, with the latest share count reaching 218 million, a new high for the past month [2] - The ETF has seen continuous net inflows over the past four days, with a maximum single-day net inflow of 6.1016 million yuan, totaling 13.3303 million yuan [2] Group 2 - The price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is currently at 23.35, which is in the 3.64% percentile for the past year, indicating that the valuation is lower than 96.36% of the time in the past year, suggesting a historical low [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index include WuXi AppTec, Innovent Biologics, BeiGene, and others, collectively accounting for 56.03% of the index [2] Group 3 - The domestic medical device industry is still in a rapid development phase, with short-term impacts from medical insurance cost control potentially affecting the sector negatively, but there is optimism for innovation-driven import substitution and global development [3] - The industry is expected to see improved competitiveness among domestic companies due to policy support and technological advancements, accelerating import substitution [3] - Investors without stock accounts can consider the Hang Seng Medical Index ETF linked fund (018433) to gain exposure to investment opportunities in the Hong Kong medical sector [3]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company achieved a revenue of 3.095 billion yuan in Q1 2025, representing a year-on-year growth of 28.3%, with a net profit of 322 million yuan, up 32.7% year-on-year [1] - The company benefits from the vehicle replacement policy, leading to sustained growth in automotive consumption, with a diverse customer base including major brands such as Volkswagen, Toyota, and Mercedes-Benz [1][2] - The company has optimized its customer structure and improved profitability through strong cost control, with a net profit margin increase from 10.06% in Q1 2024 to 10.41% in Q1 2025 [2] - The company is advancing its global strategy, focusing on R&D and partnerships with firms like Huawei, and has entered the supply chains of foreign luxury brands [3] Financial Performance - The company is projected to achieve revenues of 16.511 billion yuan, 20.460 billion yuan, and 25.398 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 24.6%, 23.9%, and 24.1% [4] - The net profit is expected to reach 1.919 billion yuan, 2.486 billion yuan, and 3.125 billion yuan for the same years, with growth rates of 36.3%, 29.5%, and 25.7% [4] - The company's earnings per share (EPS) is projected to increase from 6.72 yuan in 2025 to 10.94 yuan in 2027 [4] Customer and Product Development - The company has undertaken 69 new model development projects in 2024, with 40 models entering mass production, including high-value projects like the smart headlights for Huawei's AITO M9 [2] - The M9 model is expected to deliver 150,000 units in 2024, contributing significantly to revenue growth [2] Global Expansion - The company is making strides in global markets, with the establishment of factories in Europe, Mexico, and the USA, marking a new phase in its globalization efforts [3]

Core Viewpoint - The recent divestment of all Pop Mart shares by Fengqiao Capital has sparked significant discussion, with the company's stock price rising despite the sell-off, indicating strong underlying value and market confidence in Pop Mart's long-term prospects [1][2]. Group 1: Stock Performance and Market Reaction - Following the initial share reduction on April 30, Pop Mart's stock price only dipped by 0.3% before rebounding by 4.7% the next day, demonstrating resilience [2]. - The stock experienced a cumulative increase of 6.3% over three trading days after the second reduction, and a further rise of 3.85% on May 9, indicating a trend of "selling leading to rising" [2]. - Year-to-date, Pop Mart's stock has surged over 100%, with a market capitalization of HKD 257.3 billion as of May 9 [1]. Group 2: Financial Performance and Growth - In 2024, Pop Mart achieved revenue of CNY 13.04 billion, a year-on-year increase of 106.9%, and an adjusted net profit of CNY 3.4 billion, up 185.9% [3][4]. - The first quarter of 2025 saw revenue growth of 165% to 170%, with domestic revenue increasing by 95% to 100% and overseas revenue soaring by 475% to 480% [3]. Group 3: Market Position and Future Outlook - Analysts highlight Pop Mart's strong IP operation capabilities and global expansion potential as key competitive advantages, with overseas revenue expected to account for nearly 40% in 2024 [4]. - The company plans to expand into the European and American markets in 2025, aiming to replicate its Asian growth trajectory [4]. - Recent reports indicate that over 20 investment banks have issued "buy" ratings for Pop Mart, reflecting high market confidence in its growth prospects [4].

Core Viewpoint - Yinlun Co., Ltd. plans to implement a share buyback program to enhance employee stock ownership and incentive plans, with a budget between 50 million and 100 million yuan [1][2]. Group 1: Share Buyback Plan - The company intends to repurchase shares through centralized bidding, with a total expenditure of no less than 50 million yuan and no more than 100 million yuan, estimating to buy back between 1.2888 million and 2.7777 million shares, which accounts for 0.17% to 0.33% of the total share capital [2]. - The funding for the buyback will come from the company's own funds and a special loan for stock repurchase, with a commitment letter from the Bank of China Zhejiang Branch agreeing to provide a loan of up to 90 million yuan [2]. Group 2: Financial Performance - Yinlun's revenue increased from 1.684 billion yuan in 2012 to 11.02 billion yuan in 2023, representing a growth of 554.39%, while net profit rose from 41 million yuan to 612 million yuan, a staggering increase of 1392.7% [4]. - In 2024, the company achieved revenue of 12.7 billion yuan, a year-on-year increase of 15.28%, and net profit of 784 million yuan, up 28% from the previous year [4]. - For Q1 2025, the company reported revenue of 3.416 billion yuan, a year-on-year growth of 15.05%, and net profit of 212 million yuan, up 10.89% [6]. Group 3: Research and Development - The company has invested a total of 2.044 billion yuan in R&D from 2020 to 2024, with annual expenditures increasing each year [6]. - R&D expenses for the years 2020 to 2024 were 269 million yuan, 326 million yuan, 386 million yuan, 490 million yuan, and 573 million yuan respectively [6]. Group 4: Market Position and Strategy - Yinlun specializes in the research, manufacturing, and sales of various heat management and exhaust after-treatment products, maintaining the top position in the domestic market for heat exchangers for over a decade [2]. - The company has expanded its international operations, with significant revenue growth in North America and Europe, achieving a 50.47% increase in self-operated business income in North America [6].